MetaCap

Minerva Neurosciences Inc (NERV)

NASDAQ: NERVHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.00-0.12 (-5.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NERV stock chart

Technical analysis

Key statistics

All statistics
Market cap
$99.67M
EPS (TTM)
-$33.83
52-week range
1.96 – 8.80
Day range
1.99 – 2.12
Volume / Avg
137.66K / 164.71K
Beta
—

52-week range

$1.96$8.80

NERV stock today

Minerva Neurosciences (NERV) closed at $2.00 on Nov 20, down 5.66% (-$0.12), versus the S&P 500's 3.70% decline. Shares are 77.3% below their 52-week high of $8.80, set on Mar 16, 2026 and 2.0% above the 52-week low of $1.96, near the bottom of the past year's range. NERV is down 50.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.2%.

Minerva Neurosciences has posted a net loss over the last twelve months (EPS of -$33.83), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Minerva Neurosciences

Company profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Remy Luthringer Ph.D.
Headquarters
Burlington, MA
Employees
7
IPO year
2014

Financial highlights

Full financials

Minerva Neurosciences reported a net loss of $293.4 million, compared with net income of $1.4 million a year earlier. Diluted earnings per share came in at -$34.67, down from $0.19.

Minerva Neurosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—$0$0$0$0
Growth————-100.00%
Net income$-293.42M$1.44M$-30.01M$-32.11M$-49.91M
EPS (diluted)$-34.67$0.19$-4.61$-6.01$-9.35

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$10.33+416.50%

  • Strong buy 1
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-1.60 vs $-0.14
Surprise
-1042.86%

NERV news

All NERV news

Minerva Neurosciences peers

Health Care sector
NERV peer companies
CompanyPrice% ChgMarket capCompare
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs NERV
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs NERV
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs NERV
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs NERV
FHTXFoghorn Therapeutics Inc.1.72-3.37%$103.14Mvs NERV
GNLXGenelux Corporation2.17-4.82%$103.36Mvs NERV
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs NERV
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs NERV

Indexes, lists and sector

Minerva Neurosciences stock FAQ

What is Minerva Neurosciences's stock price today?

NERV last traded at $2.00 as of Nov 20, 4:00 PM EST, down 5.66% on the day. Prices are delayed at least 15 minutes.

Does Minerva Neurosciences pay a dividend?

No. Minerva Neurosciences does not currently pay a regular cash dividend.

Who is Minerva Neurosciences's CEO?

Dr. Remy Luthringer Ph.D. is the chief executive officer of Minerva Neurosciences Inc, which has about 7 employees.

Has NERV ever split its stock?

Yes. The most recent NERV stock split was a 1-for-8 split on Jun 21, 2022.

What is the NERV 52-week high?

The 52-week high for NERV is $8.80 and the 52-week low is $1.96. The stock is currently 77.3% below its high.

Compare NERV